Novartis gets FDA approval for Cosentyx in pediatric hidradenitis suppurativa
Go back to Novartis gets FDA approval for Cosentyx in pediatric hidradenitis suppurativa| NOVARTIS AG (NYSE: NVS) | Delayed: 156.91 -0.68 (0.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $157.59 | 52 Week High | $89.15 | |||
| Open | $157.63 | 52 Week Low | $69.84 | |||
| Day High | $157.89 | P/E | N/A | |||
| Day Low | $155.92 | EPS | $0.00 | |||
| Volume | 1,289,556 | |||||
